Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

被引：24
|
作者：
Valle, JW
Dangoor, A
Beech, J
Sherlock, DJ
Lee, SM
Scarffe, JH
Swindell, R
Ranson, M
机构：
[1] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[2] N Manchester Grp Hosp, Pennine Acute Hosp NHS Trust, Manchester M8 5RB, Lancs, England
[3] Middlesex Hosp, London W1T 3AA, England
[4] Lister Hosp, E&N Herts NHS Trust, Stevenage SG1 4AB, Herts, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 92卷 / 04期
关键词：
pegylated liposomal doxorubicin; hepatocellular carcinoma; phase II;
D O I：
10.1038/sj.bjc.6602394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.
引用
收藏
页码：628 / 630
页数：3
相关论文
共 50 条
  • [31] Phase II pilot study of Caelyx (doxorubicin HCI, pegylated liposomal) in patients with inoperable squamous cell cancer of the head and neck
    Harrington, KJ
    Harrison, D
    Stewart, JSW
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S33 - S33
  • [32] Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin
    Jing-Houng Wang
    Hung-Da Tung
    Tai-Yi Chen
    Chao-Hung Hung
    Chien-Hung Chen
    Chi-Sin Changchien
    Tsung-Hui Hu
    Chuan-Mo Lee
    Sheng-Nan Lu
    Hepatology International, 2011, 5 : 567 - 574
  • [33] Combination of gemcitabine (GEM) and liposomal pegylate doxorubicin (PLD) in recurrent/metastatic breast carcinoma: A phase II study
    Adamo, Vincenzo
    Ferrandina, Gabriella
    Rossello, Rosalba
    Garipoli, Claudia
    Adamo, Barbara
    Masi, Maria Claudia
    Lorusso, Vito
    Condemi, Giovanni
    Ferrau, Francesco
    Scambia, Giovanni
    ANNALS OF ONCOLOGY, 2006, 17 : 74 - 74
  • [34] Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin
    Wang, Jing-Houng
    Tung, Hung-Da
    Chen, Tai-Yi
    Hung, Chao-Hung
    Chen, Chien-Hung
    Changchien, Chi-Sin
    Hu, Tsung-Hui
    Lee, Chuan-Mo
    Lu, Sheng-Nan
    HEPATOLOGY INTERNATIONAL, 2011, 5 (01) : 567 - 574
  • [35] A RANDOMIZED PHASE III STUDY OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS PLD IN RELAPSED, RECURRENT OVARIAN CANCER (OC)
    Monk, B. J.
    Herzog, T.
    Kaye, S.
    Krasner, C. N.
    Vermorken, J.
    Muggia, F.
    Pujade-Lourraine, E.
    Renshaw, F. G.
    Lebedinsky, C.
    Poveda, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 2 - 2
  • [36] Phase II trial of the combination of subcutaneous bortezomib (Bortez) and pegylated liposomal doxorubicin (PLD) for the treatment of patients with acute myelogenous leukemia (AML).
    Tomlinson, Ben Kent
    Tuscano, Joseph M.
    Abedi, Mehrdad
    Welborn, Jeanna
    O'Donnell, Robert
    Arora, Mili
    Verman, Radha
    Jones, Kelly
    Jonas, Brian Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Cardiac safety of pegylated liposomal doxorubicin (PLD) in combination with trastuzumab (T) in patients with metastatic breast cancer (MBC): Results from a multicenter phase II study
    Stickeler, E.
    Watermann, D. O.
    Woll, J.
    Foeldi, M.
    Gitsch, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Intrahepatic pegylated liposomal doxorubicin (PLD) in patients with liver malignancies
    Granetto, C.
    Fea, E.
    Colantonio, I
    Di Costanzo, G.
    Garrone, O.
    Gasco, M.
    Occelli, M.
    Heouaine, A.
    Numico, G.
    Merlano, M.
    ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
  • [39] Interim results of phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL)
    Straus, D. J.
    Duvic, M.
    Horwitz, S. M.
    Hymes, K. B.
    Goy, A.
    Hernandez-Ilizaliturri, F. J.
    Feldman, T.
    Wegner, B.
    Myskowski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma
    Fink, W
    Zimpfer-Rechner, C
    Thoelke, A
    Figl, R
    Kaatz, M
    Ugurel, S
    Schadendorf, D
    ONKOLOGIE, 2004, 27 (06): : 540 - 544
12345